Long-Term Cardiac Safety Analysis of NCCTG N9831 (Alliance) Adjuvant Trastuzumab Trial

PURPOSE: Significant improvement in survival outcomes has been established with the addition of trastuzumab to adjuvant chemotherapy for human epidermal growth factor receptor 2 (HER2) –positive early breast cancer treatment. However, trastuzumab may increase the risk of cardiac toxicity, and long-t...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Clin Oncol
Hlavní autoři: Advani, Pooja P., Ballman, Karla V., Dockter, Travis J., Colon-Otero, Gerardo, Perez, Edith A.
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Clinical Oncology 2016
Témata:
ORIGINAL REPORTS
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4980566/
https://ncbi.nlm.nih.gov/pubmed/26392097
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2015.61.8413
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky